Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 1
2004 2
2005 1
2006 1
2011 1
2012 1
2022 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis.
Moinuddin R, deTineo M, Maleckar B, Naclerio RM, Baroody FM. Moinuddin R, et al. Ann Allergy Asthma Immunol. 2004 Jan;92(1):73-9. doi: 10.1016/S1081-1206(10)61713-9. Ann Allergy Asthma Immunol. 2004. PMID: 14756468 Clinical Trial.
When the change from baseline was analyzed, there were no statistically significant differences in total symptoms between fexofenadine-pseudoephedrine and loratadine-montelukast (median, -28.5 vs -22.5; P = .33). ...The lack of improvement in sleep in the fexofen …
When the change from baseline was analyzed, there were no statistically significant differences in total symptoms between fexofenadine …
Exposure of Fexofenadine, but Not Pseudoephedrine, Is Markedly Decreased by Green Tea Extract in Healthy Volunteers.
Misaka S, Ono Y, Taudte RV, Hoier E, Ogata H, Ono T, König J, Watanabe H, Fromm MF, Shimomura K. Misaka S, et al. Clin Pharmacol Ther. 2022 Sep;112(3):627-634. doi: 10.1002/cpt.2682. Epub 2022 Jun 29. Clin Pharmacol Ther. 2022. PMID: 35678032 Free PMC article. Clinical Trial.
The purpose of this study was to investigate whether pharmacokinetics of fexofenadine and pseudoephedrine are affected by catechins, major GT components. A randomized, open, 2-phase crossover study was conducted in 10 healthy Japanese volunteers. ...On the contrary, …
The purpose of this study was to investigate whether pharmacokinetics of fexofenadine and pseudoephedrine are affected by cate …
Effect of fexofenadine/pseudoephedrine combination tablet on nasal obstruction in patients with allergic rhinitis using rhinomanometry: A randomized controlled trial.
Nakamura Y, Yokoyama Y, Koyama S, Fujiwara K, Nakamori M, Fujii T, Enomoto T, Takeuchi H. Nakamura Y, et al. Asian Pac J Allergy Immunol. 2024 Jun;42(2):147-153. doi: 10.12932/AP-160920-0963. Asian Pac J Allergy Immunol. 2024. PMID: 33638625 Free article. Clinical Trial.
BACKGROUND: A fexofenadine/pseudoephedrine combination tablet (F/P) is an optimal product for nasal obstruction. It contains fexofenadine hydrochloride, a histamine H1-receptor antagonist for sneezing and rhinorrhea and pseudoephedrine hydrochloride, a …
BACKGROUND: A fexofenadine/pseudoephedrine combination tablet (F/P) is an optimal product for nasal obstruction. It contains …
The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis.
Sussman GL, Mason J, Compton D, Stewart J, Ricard N. Sussman GL, et al. J Allergy Clin Immunol. 1999 Jul;104(1):100-6. doi: 10.1016/s0091-6749(99)70120-x. J Allergy Clin Immunol. 1999. PMID: 10400846 Clinical Trial.
OBJECTIVE: We sought to compare the efficacy and safety of a fexofenadine HCl/pseudoephedrine HCl combination with that of each individual component in the treatment of ragweed allergy. METHODS: In this Canadian multicenter, double-blind, parallel-group study, 651 p …
OBJECTIVE: We sought to compare the efficacy and safety of a fexofenadine HCl/pseudoephedrine HCl combination with that of eac …
Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit.
Berkowitz RB, Woodworth GG, Lutz C, Weiler K, Weiler J, Moss M, Meeves S. Berkowitz RB, et al. Ann Allergy Asthma Immunol. 2002 Jul;89(1):38-45. doi: 10.1016/S1081-1206(10)61909-6. Ann Allergy Asthma Immunol. 2002. PMID: 12141718 Clinical Trial.
Onset of relief for fexofenadine-pseudoephedrine (n = 148) was 45 minutes postdose (MSC, P = 0.0127; total symptom complex, P = 0.0380). ...Decrease in headache with fexofenadine-pseudoephedrine versus placebo began 45 minutes postdose (P = 0.0425). In …
Onset of relief for fexofenadine-pseudoephedrine (n = 148) was 45 minutes postdose (MSC, P = 0.0127; total symptom complex, P …
Single-dose and steady-state bioequivalence of fexofenadine and pseudoephedrine combination tablets compared with individual formulations in healthy adults.
Howard DR, Haribhakti R, Kittner B, Agrawala P. Howard DR, et al. Curr Med Res Opin. 2005 May;21(5):769-76. doi: 10.1185/030079905x43703. Curr Med Res Opin. 2005. PMID: 15969876 Clinical Trial.
OBJECTIVE: A 24-h extended-release formulation of fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg (FEX 180 mg/PSE 240 mg) has recently been approved by the US Food and Drug Administration for symptom relief of seasonal allergic rhinitis, including nasal congestio …
OBJECTIVE: A 24-h extended-release formulation of fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg (FEX 180 mg/PSE 240 mg) h …
Fexofenadine HCl 60 mg/ pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment of seasonal allergic rhinitis symptoms, as assessed in an allergen exposure unit.
Berkowitz RB, McCafferty F, Lutz C, Bazelmans D, Godfrey P, Meeves S, Liao Y, Georges G. Berkowitz RB, et al. Allergy Asthma Proc. 2004 Sep-Oct;25(5):335-43. Allergy Asthma Proc. 2004. PMID: 15603207 Clinical Trial.
This randomized, double-blind, placebo-controlled, parallel-group study investigated the onset of action, efficacy, and safety of fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg or placebo in patients with moderate-to-severe seasonal allergic rhinitis in an allerg …
This randomized, double-blind, placebo-controlled, parallel-group study investigated the onset of action, efficacy, and safety of fexofen …
Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged 12 years with moderate to severe seasonal allergic rhinitis: a pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies.
Berkowitz RB, McCafferty F, Lutz C, Bazelmans D, Godfrey P, Meeves S, Liao Y, Georges G. Berkowitz RB, et al. Clin Ther. 2006 Oct;28(10):1658-69. doi: 10.1016/j.clinthera.2006.10.023. Clin Ther. 2006. PMID: 17157121 Clinical Trial.
OBJECTIVE: This was a pooled analysis of 2 published studies with identical designs investigating the onset of action of the combination of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg (FEX60/PSE120) in subjects with moderate to severe SAR. …
OBJECTIVE: This was a pooled analysis of 2 published studies with identical designs investigating the onset of action of the combination of …
The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms.
Stokes JR, Romero FA Jr, Allan RJ, Phillips PG, Hackman F, Misfeldt J, Casale TB. Stokes JR, et al. J Allergy Clin Immunol. 2012 Feb;129(2):409-12, 412.e1-2. doi: 10.1016/j.jaci.2011.11.026. Epub 2011 Dec 22. J Allergy Clin Immunol. 2012. PMID: 22196768 Clinical Trial.
Treatments included 10 mg of PF-03654746 plus 60 mg of fexofenadine (group 1), 1 mg of PF-03654746 plus 60 mg of fexofenadine (group 2), 60 mg of fexofenadine/120 mg of pseudoephedrine (group 3), and placebo (group 4). ...There was no significant effec …
Treatments included 10 mg of PF-03654746 plus 60 mg of fexofenadine (group 1), 1 mg of PF-03654746 plus 60 mg of fexofenadine …